Note: Ingredients listed on restricted chemical lists
EC/CAS
215-185-5/1310-73-2
Name of the chemical
sodium hydroxide
Concentration
1-<5%
General Information
Version
2,0 - Replaces version 1,00
Revision date
2023-05-15
Product name
EDTA Decalcifying Solution 25 %
Emergency telephone
Mainz, Germany, Tel +49(0)6131/19240
Icons in SDS
Company Information
company name
MORPHISTO GmbH
e-mail address of the competent person responsible for the Safety Data Sheet
info@morphisto.de, gefahrstoffmanagement@morphisto.de
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H315, H319, H373
Hazard statements
Code
Statements
H315
Causes skin irritation
Section 2
2.1 Classification of the substance or mixture
GB CLP Regulation Skin Irrit. 2; H315 Eye Irrit. 2; H319 STOT RE 2; H373
Hazard statements
see SECTION 16 H315 Causes skin irritation. H319 Causes serious eye irritation. H373 May cause damage to organs through prolonged or repeated exposure.
2.2 Label elements
GB CLP Regulation
Hazardous Ingredients
Disodium dihydrogen ethylenediaminetetraacetate
Signal word
Warning Warning
Precautionary statements
P260 Do not breathe dust/fume/gas/mist/vapours/spray. P280 Wear protective gloves/protective clothing/eye protection/face protection. P337+P313 If eye irritation persists: Get medical advice/attention. P314 Get medical advice/attention if you feel unwell. Labelling of packages where the contents do not exceed 125 ml
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulating and toxic (PBT) or very persistent and very bioaccumulating (vPvB) at levels of 0.1% or higher. Ecological information: The substance/mixture does not contain any components that are considered to be hazardous according to REACH Article 57(f) or Commission Delegated Regulation (EU) 2017/2100 or Commission Delegated Regulation (EU) 2018/605 in amounts of 0.1 % or more have endocrine disrupting properties. Toxicological information: The substance/mixture does not contain any components that are to be classified according to REACH Article 57(f) or Commission Delegated Regulation (EU) 2017/2100 or Commission Delegated Regulation (EU) 2018/605 in quantities of 0.1 % or more have endocrine disrupting properties.
